The Evolving Role of Targeted Therapies in Chronic Lymphocytic Leukemia Care
By
[email protected] (Linda Maxwell)
12d agoen
Source
ltcnews.comThe Evolving Role of Targeted Therapies in Chronic Lymphocytic Leukemia Careltcnews.comChronic lymphocytic leukemia (CLL) is the most common leukemia in adults and primarily affects people over age 60. Advances in targeted therapies have transformed treatment by attacking leukemia cells more precisely than traditional chemotherapy, allowing many patients to live longer with fewer side effects while maintaining independence and quality of life.
You might also wanna read
Leukemia No Longer Incurable, Stem Cell Transplants Boost Cure Rates Even in Elderly
Seoul Economic Daily·2d ago
Targeting genomic instability: From chemotherapy to precision medicine in cancer treatment
This article examines genomic instability as a hallmark of cancer, explaining how it drives malignant transformation through accumulated gen
cell.com·24d ago
Cancer therapies in 2026: a new era of hope
مجلة المجلة | مجلة العرب الدولية·1d ago
Teen becomes first person saved by CRISPR base editing after leukaemia treatment
13-year-old Alyssa Tapley, diagnosed with leukaemia, was told she had only weeks to live after a failed bone marrow transplant. She became t
newscientist.com·7d agoTeen becomes first person saved by CRISPR base editing after leukaemia treatment
13-year-old Alyssa Tapley, diagnosed with leukaemia, was told she had only weeks to live after a failed bone marrow transplant. She became t
newscientist.com·7d ago
New antibody shows promise for blocking Epstein-Barr virus linked to cancer and autoimmune disease
Epstein-Barr virus (EBV) is carried by 95% of people, usually lying dormant but linked to serious diseases like multiple sclerosis, lupus, r
gavi.org·5d ago
Researchers identify biological markers of treatment-resistant aggressive lymphoma
Researchers from Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified biological features that distinguish particul
news-medical.net·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.